$11.69
0.93% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US7027121000
Symbol
PASG

Passage Bio Inc Stock price

$11.69
+3.66 45.58% 1M
+3.56 43.86% 6M
-0.11 0.93% YTD
-4.91 29.58% 1Y
-15.91 57.64% 3Y
-550.71 97.92% 5Y
-432.31 97.37% 10Y
-432.31 97.37% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.11 0.93%
ISIN
US7027121000
Symbol
PASG
Industry

Key metrics

Basic
Market capitalization
$36.5m
Enterprise Value
$-16.3m
Net debt
positive
Cash
$52.8m
Shares outstanding
3.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.5
P/B
1.2
Financial Health
Equity Ratio
59.8%
Return on Equity
-105.7%
ROCE
-90.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-45.8m | $-74.9m
EBIT
$-47.1m | $-44.7m
Net Income
$-45.3m | $-34.3m
Free Cash Flow
$-33.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
30.8% | -20.6%
EBIT
32.1% | 31.4%
Net Income
34.2% | 47.0%
Free Cash Flow
43.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-14.2
FCF per Share
$-10.5
Short interest
0.7%
Employees
60
Rev per Employee
$0.0
Show more

Is Passage Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Passage Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Passage Bio Inc forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Passage Bio Inc forecast:

Buy
92%
Hold
8%

Financial data from Passage Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 20 20
26% 26%
-
- Research and Development Expense 27 27
36% 36%
-
-46 -46
31% 31%
-
- Depreciation and Amortization 1.27 1.27
60% 60%
-
EBIT (Operating Income) EBIT -47 -47
32% 32%
-
Net Profit -45 -45
34% 34%
-

In millions USD.

Don't miss a Thing! We will send you all news about Passage Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Passage Bio Inc Stock News

Neutral
GlobeNewsWire
about 2 months ago
Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study Aligned with the U.S. Food and Drug Administration (FDA) on an analytical approach to establish comparability of a high-productivity, suspension-based PBFT02 manufacturing process On track to obtain regulatory feedback on FTD-GRN registrational trial design in 1H 2026 Cash runway into 1Q 2027 PHI...
Neutral
GlobeNewsWire
about 2 months ago
PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will participate in a fireside chat during the Guggenheim Securities 2nd Annual Healthcare Innovation Conference on Wed...
Neutral
GlobeNewsWire
3 months ago
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will participate in a panel discussion during the Chardan 9th Annual Genetic Medicines Conference on Tuesday, October 2...
More Passage Bio Inc News

Company Profile

Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

Head office United States
CEO William Chou
Employees 60
Founded 2017
Website www.passagebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today